Efficacy of TCA Effect on Varicella Atrophic Scars
January 16, 2007 updated by: Shahid Beheshti University of Medical Sciences
Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars
This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars.
According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.
Study Type
Interventional
Enrollment
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 198994148
- Recruiting
- Skin Research Center, Shohada-e Tajrish Hospital, Shaheed Beheshti Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 45 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Atrophic varicella scar on face
Exclusion Criteria:
- Active varicella infection
- Active Herpetic infection
- Previous history of keloid formation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Objective Clearance(before and after photographies were taken)
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Subjective Clearance(according to the patients satisfaction)
|
|
Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Parviz Toossi, M.D., Skin Research Center of Shaheed Beheshti medical University
- Principal Investigator: Behrooz Barikbin, M.D., Skin Research Center of Shaheed Beheshti Medical Universty
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
January 16, 2007
First Submitted That Met QC Criteria
January 16, 2007
First Posted (Estimate)
January 17, 2007
Study Record Updates
Last Update Posted (Estimate)
January 17, 2007
Last Update Submitted That Met QC Criteria
January 16, 2007
Last Verified
January 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SRC-BBA-1385-6-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.